Takeda Pharmaceutical Company Limited provided consolidated earnings guidance for the fiscal year ending March 31, 2023. The company expects revenue to be JPY 3,690,000 million, Operating profit to be JPY 520,000 million, net profit attributable to owners of parent to be JPY 292,000 million or JPY 188.13 per basic share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4,134 JPY | 0.00% | +0.10% | +1.97% |
May. 16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
May. 15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.97% | 41.33B | |
+38.51% | 727B | |
+33.05% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.09% | 205B | |
-5.77% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- 4502 Stock
- News Takeda Pharmaceutical Company Limited
- Takeda Pharmaceutical Company Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023